დასაწყისი · კატალოგი · პროფილი · ცხრილი
ჯანდაცვა BODY HANDBOOK
ჯანდაცვა · §633
Low Libido
You stopped wanting it. A year, maybe two now, and you've made peace with it — adulthood, the antidepressant, that's forty. Most of the time the story is wrong. Persistent low desire is the symptom of a short list of fixable causes — a medication nobody has reviewed, snoring that turned out to be sleep apnea, a depression you'd stopped naming, a hormone nobody has measured. A couple of hours of unglamorous workup catches a real share of them; the part of you that had gone quiet usually wasn't supposed to.
Respond · As-needed Evidence Moderate თავი ჯანდაცვა

Sometimes it's the SSRI you've been on for years; sometimes it's the snoring your partner mentions; sometimes it's a depression you've mistaken for tired; sometimes it's a hormone nobody has tested. Each has a name, and the names point at fixes. The lag between treating the right thing and feeling something change is weeks to a few months — not the indefinite you'll have to live with it that gets quietly substituted.

Wanting isn't a single drive that goes up or down on its own. It's the net of two systems: an excitement circuit — dopamine, testosterone, novelty, the chemistry that lights up at a glance across the room — and a brake — serotonin, prolactin, anxiety, pain, anger — that pushes the other way Bancroft 2009. Low desire is what happens when one side wins for long enough, and the two ways of getting there look identical from the outside: the brake locked on (the antidepressant, the chronic stress, the pelvic pain, the unresolved fight), or the gas pedal flattened (the testosterone too low to register, the sleep too short to make it, the body too inflamed to care). The interventions that fix one don't touch the other. The reason people stay stuck for years is that they keep treating the wrong half.

This is why the workup looks weirdly broad. A clinician who jumps straight to hormones is going to miss the SSRI; one who jumps to therapy is going to miss the sleep apnea. The honest version is a sequence: rule out the brake, rule out the missing gas, then talk about the relationship and the head. Most of the high-yield finds — the medication nobody has reviewed, the snoring, the unrecognized depression, the thyroid — sit in the first two rooms.

What you lose by living with it

It doesn't get loud. The bedroom goes quieter, then the dinners go quieter, and the version of you that used to flirt with your partner just stops showing up. Three years in, neither of you can remember which side stopped first. The relationship starts to organise itself around the absence — the careful avoidance of initiation that becomes its own habit, the slow accommodation that gets called maturity. The couple-research literature is consistent that persistent, untreated desire discrepancy is one of the more reliable predictors of long-term relationship dissatisfaction; the damage shows up downstream, not in the moment.

The medical stakes are quieter and harder to see at home. Middle-aged men with sustained loss of interest carry higher rates of subclinical cardiovascular disease and undiagnosed obstructive sleep apnea than peers with intact desire Buvat et al. 2010. Women with persistent low desire and distress are roughly twice as likely to be carrying an unrecognized depression — the relationship runs both ways, and either direction routes through the same nervous system Atlantis & Sullivan 2012. What you lose when you don't ask is two things: a part of your life that was supposed to come back, and the chance to catch something quieter that's already started.

Three things almost everyone gets wrong

Low desire is not the same thing as low testosterone, especially in men. Roughly two-thirds of men who turn up with persistent loss of interest have normal total testosterone on a proper morning measurement Buvat et al. 2010. The SSRI, the snoring, and the relationship rut are statistically more common causes than hypogonadism. Direct-to-consumer testosterone clinics that prescribe without two morning measurements and without ruling out the cheap upstream stuff aren't helping the median patient — they're treating a number that wasn't the problem, and shutting down the body's own production along the way.

Erection drugs (sildenafil, tadalafil — the pills ending in -afil) don't treat desire. They treat the plumbing on the way out. A man who wants to but can't hold an erection responds. A man whose interest has gone but whose erections still work does not. The molecule has no central effect on wanting.

For women, responsive desire is desire. The model that's quietly become standard in sex medicine is Rosemary Basson's: spontaneous, intrusive, I want this right now desire is one valid pattern, more typical of men. Desire that emerges in context — once the touch has started, once the day has been put down, once you remember you wanted to want — is also normal Basson 2001. Many women who think they've lost desire have a pattern that was never measured against the right yardstick. The reframe alone resolves a meaningful share of presentations.

The actual workup

There isn't a single libido test; there's a sequence designed to fall through to whichever cause is doing the work. The Endocrine Society's male-hypogonadism guideline and the International Society for the Study of Women's Sexual Health process of care converge on a similar shape — start with the cheap, high-yield questions, escalate to labs only when the answers haven't already arrived Bhasin et al. 2018 Clayton et al. 2018.

One detail about the testosterone draw worth holding onto: roughly a third of single low values come back normal on retesting, because assays vary and testosterone has a daily rhythm that peaks in the morning Bhasin et al. 2018. A single low number is not a diagnosis. It's the prompt for the second one. Any clinic prescribing replacement on one draw is skipping the part of the guideline that actually protects you.

Where the workup goes wrong

Jumping to testosterone. Online TRT clinics treat low energy and low desire as if they were always low T. They prescribe without two morning draws, without screening for sleep apnea, without reviewing antidepressants, without asking about opioids. The Endocrine Society explicitly warns against testosterone for men with non-specific symptoms and unconfirmed biochemical hypogonadism Bhasin et al. 2018. Once external testosterone is on board, the body's own production gets suppressed, sperm production can stop, and the cause that was actually doing the work is still there — usually still doing it.

Missing sleep apnea. A heavyset 45-year-old man whose desire has dropped over two years, who snores, who's tired in the afternoons, has a higher prior probability of obstructive sleep apnea than of primary hypogonadism. Treating the apnea with CPAP can restore both testosterone and desire without lifelong replacement Andersen & Tufik 2008. A lot of OSA gets diagnosed at all only because somebody asked the libido question.

Blaming the depression for what the antidepressant is doing. SSRIs cause sexual dysfunction in roughly 30–60% of users, paroxetine and citalopram at the high end Higgins et al. 2010. The prescribing conversation rarely names this; the patient assumes their illness is responsible. The remedy is rarely quitting the antidepressant — it's a switch, often to bupropion (low sexual side-effect profile, sometimes added to an SSRI to counter it), mirtazapine, or vortioxetine. Stoicism is not the recommended option.

Treating one half of a couple problem. When one partner consistently wants more, the lower-desire partner gets framed as the problem. That model has been out of date in the couple-research literature for decades. Sustained desire mismatch is a relational phenomenon — duration, conflict, the loss of novelty, the buildup of unspoken accommodations — and trying to solve it by working on the lower-desire partner alone is solving for half of the equation. Couples therapy and an honest conversation about the predictable arc of long-term partnered desire is the right unit of treatment.

Sex and life stage change the shape

Total testosterone declines by roughly 1% per year from the early thirties. Most of this never reaches a level where treatment helps. The threshold the guidelines work to is below about 230–300 ng/dL on two properly run morning draws, repeated Bhasin et al. 2018. Above that, the workup keeps going elsewhere — sleep, weight, antidepressant, opioid, depression, relationship. Symptomatic confirmed low T treated with replacement produces small-to-moderate desire gains, real but not the return-to-twenty that the marketing implies Snyder et al. 2016. Lifestyle moves the number too: every kilogram of sustained weight loss is associated with a small but real testosterone rise, and a structured lifestyle programme on its own improved sexual function in overweight men with low-normal levels in the largest recent trial Wittert et al. 2021.

Three life-stage effects matter. Perimenopause and after: estrogen drop produces vaginal dryness and painful sex, which sets up a learned avoidance that gets misread as low desire. Local vaginal estrogen or vaginal DHEA is first-line, dramatically underused, and not the same as systemic hormone therapy — it stays in the tissue Portman & Gass 2014 Simon et al. 2018. Postpartum and lactation: ovarian function is suppressed for months to a year — normal, not a workup target. Hormonal contraception: about 15% of users have a real downward effect on desire, often through a drop in free testosterone caused by the ethinylestradiol in combined pills; switching method is a reasonable trial Pastor et al. 2013. For postmenopausal women with persistent distressing low desire after the workup and local treatments, transdermal testosterone at physiological doses is the only pharmacotherapy supported by international consensus — though no formulation is currently FDA-approved for women in the US, which leaves access through compounded preparations and individual clinician judgement Davis et al. 2019.

For both sexes, the same upstream factors are quietly doing more damage than people realise. A week of under-five-hour nights drops daytime testosterone by 10–15% in healthy young men — about a decade's worth of aging packed into seven days Leproult & Van Cauter 2011. Sustained stress lifts cortisol and shifts the whole system toward the brake; in lab psychophysiology, women whose cortisol rises in response to erotic stimuli report more distraction and lower function than women whose cortisol falls — same stimulus, opposite endocrine response, opposite outcome Hamilton, Rellini & Meston 2008. The fix is upstream, not in the bedroom.

How it actually comes back

When the workup catches the cause, the lag between fix and felt change is weeks to a few months — not the indefinite you'll have to live with it that gets quietly substituted by everyone who hasn't bothered to ask.

The shape that arrives doesn't replay being twenty. It's smaller and more credible. The version of you that used to flirt back walks back into the room. A morning that used to start in the chemical fog of an under-treated depression starts with something quieter and more available. The partner who'd stopped initiating — because every initiation had become a careful no — stops bracing for it. Inside six months, a couple that had been performing accommodation around the silence stops needing to. Inside a year, the year you'd written off looks like a year you got back.

Concretely: switching paroxetine to bupropion shows desire returning in the 2-to-6-week range Higgins et al. 2010. CPAP for newly diagnosed sleep apnea brings morning testosterone back into normal range over one to three months Andersen & Tufik 2008. Confirmed-hypogonadism testosterone replacement produces noticeable desire change at three to six months, plateauing by twelve Snyder et al. 2016. Vaginal estrogen for menopausal dryness makes sex stop hurting within weeks; the avoidance pattern then unlearns over the next quarter Portman & Gass 2014. Mindfulness-based group therapy for women's low desire holds its gains at six-month follow-up Brotto & Basson 2014. The number worth holding onto is that the relevant timescale is weeks to months — and that the first move is the conversation, not a pill.

Things that often come up in the same conversation

Erectile dysfunction is related but distinct — it's the mechanics, not the wanting, and it responds to pills that desire doesn't. Sleep apnea is the most under-diagnosed upstream cause of mid-life male libido drop and earns its own workup. Testosterone therapy is its own decision, with real benefits in confirmed hypogonadism and real risks outside it. The menopause transition and hormone replacement live next door to this and overlap heavily. Depression screening and treatment is what catches the largest single shared mechanism. And for couples where no organic cause turns up, the relationship and couples-therapy literature is what the evidence base actually points at — not another lab panel.

·
633